Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14371524 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL12592372 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL13473846 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL14065595 | 0.89 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL14065597 | 0.89 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL13041171 | 0.87 | MEN1 (0.42) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL13671200 | 0.87 | MEN1 (0.42) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL13473844 | 0.83 | SLC6A3 (0.53) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL12592383 | 0.83 | SLC6A3 (0.53) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 | |
| SCHEMBL13473847 | 0.83 | SLC6A3 (0.53) | SLC6A2SLC6A4SLC6A3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| US-7872022-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | AHR, AR, CYP8B1 | SLC6A2 2378/4885SLC6A4 2893/4885SLC6A3 2693/4885 |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | SLC6A4, SLC6A1, SLC1A2 | SLC6A2 6/4885SLC6A4 1/4885SLC6A3 4/4885 |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A1, SLC1A2 | SLC6A2 6/4885SLC6A4 1/4885SLC6A3 4/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | SLC6A2 2332/4885SLC6A4 3061/4885SLC6A3 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.